Cargando…
Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617925/ https://www.ncbi.nlm.nih.gov/pubmed/31346315 http://dx.doi.org/10.1155/2019/8147803 |
_version_ | 1783433803610456064 |
---|---|
author | Quirant-Sánchez, Bibiana Presas-Rodriguez, Silvia Mansilla, María José Teniente-Serra, Aina Hervás-García, José V. Brieva, Luis Moral-Torres, Ester Cano, Antonio Munteis, Elvira Navarro-Barriuso, Juan Martínez-Cáceres, Eva M. Ramo-Tello, Cristina |
author_facet | Quirant-Sánchez, Bibiana Presas-Rodriguez, Silvia Mansilla, María José Teniente-Serra, Aina Hervás-García, José V. Brieva, Luis Moral-Torres, Ester Cano, Antonio Munteis, Elvira Navarro-Barriuso, Juan Martínez-Cáceres, Eva M. Ramo-Tello, Cristina |
author_sort | Quirant-Sánchez, Bibiana |
collection | PubMed |
description | Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1(CM) cells (relapsed: 11.60 ± 4.17%vs. nonrelapsed: 9.25 ± 3.17%, p < 0.05) and Th1Th17(CM) cells (relapsed: 15.65 ± 6.15%vs. nonrelapsed: 10.14 ± 4.05%, p < 0.01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17(CM) (CD4(+)CCR7(+)CD45RA(−)CCR6(+)CXCR3(+)) cells > 11.48% had a 50% relapse-free survival compared to patients with Th1Th17(CM)cells < 11.48% whose relapse-free survival was 88% (p = 0.013, log-rank test). Additionally, a high percentage of Th1Th17(CM) cells was also found in patients with MRI activity (MRI activity: 14.02 ± 5.87%vs. no MRI activity: 9.82 ± 4.06%, p < 0.01). Our results suggest that the percentage of Th1Th17(CM) lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment. |
format | Online Article Text |
id | pubmed-6617925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-66179252019-07-25 Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment Quirant-Sánchez, Bibiana Presas-Rodriguez, Silvia Mansilla, María José Teniente-Serra, Aina Hervás-García, José V. Brieva, Luis Moral-Torres, Ester Cano, Antonio Munteis, Elvira Navarro-Barriuso, Juan Martínez-Cáceres, Eva M. Ramo-Tello, Cristina Mediators Inflamm Research Article Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1(CM) cells (relapsed: 11.60 ± 4.17%vs. nonrelapsed: 9.25 ± 3.17%, p < 0.05) and Th1Th17(CM) cells (relapsed: 15.65 ± 6.15%vs. nonrelapsed: 10.14 ± 4.05%, p < 0.01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17(CM) (CD4(+)CCR7(+)CD45RA(−)CCR6(+)CXCR3(+)) cells > 11.48% had a 50% relapse-free survival compared to patients with Th1Th17(CM)cells < 11.48% whose relapse-free survival was 88% (p = 0.013, log-rank test). Additionally, a high percentage of Th1Th17(CM) cells was also found in patients with MRI activity (MRI activity: 14.02 ± 5.87%vs. no MRI activity: 9.82 ± 4.06%, p < 0.01). Our results suggest that the percentage of Th1Th17(CM) lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment. Hindawi 2019-06-26 /pmc/articles/PMC6617925/ /pubmed/31346315 http://dx.doi.org/10.1155/2019/8147803 Text en Copyright © 2019 Bibiana Quirant-Sánchez et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Quirant-Sánchez, Bibiana Presas-Rodriguez, Silvia Mansilla, María José Teniente-Serra, Aina Hervás-García, José V. Brieva, Luis Moral-Torres, Ester Cano, Antonio Munteis, Elvira Navarro-Barriuso, Juan Martínez-Cáceres, Eva M. Ramo-Tello, Cristina Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title | Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title_full | Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title_fullStr | Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title_full_unstemmed | Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title_short | Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment |
title_sort | th1th17(cm) lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617925/ https://www.ncbi.nlm.nih.gov/pubmed/31346315 http://dx.doi.org/10.1155/2019/8147803 |
work_keys_str_mv | AT quirantsanchezbibiana th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT presasrodriguezsilvia th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT mansillamariajose th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT tenienteserraaina th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT hervasgarciajosev th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT brievaluis th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT moraltorresester th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT canoantonio th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT munteiselvira th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT navarrobarriusojuan th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT martinezcaceresevam th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment AT ramotellocristina th1th17cmlymphocytesubpopulationasapredictivebiomarkerofdiseaseactivityinmultiplesclerosispatientsunderdimethylfumarateorfingolimodtreatment |